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Although the majority of Lyme disease patients can be cured, at least 10–20% of the
patients continue to suffer from persisting symptoms such as fatigue, muscular and
joint pain, and neurologic impairment after standard 2–4 week antibiotic treatment.
While the causes for this post-treatment Lyme disease symptoms are unclear, one
possibility is due to Borrelia burgdorferi persisters that are not effectively killed by
current antibiotics such as doxycycline or amoxicillin used to treat Lyme disease.
A previous study showed that four rounds of ceftriaxone pulse dosing treatment
eradicated B. burgdorferi persisters in vitro using a relatively young late log phase
culture (5 day old). In this study, we investigated if ceftriaxone pulse dosing could
also eradicate B. burgdorferi persisters in older stationary phase cultures (10 day old)
enriched with more resistant microcolony form of persisters. We found that ceftriaxone
pulse dosing could only eradicate planktonic log phase B. burgdorferi spirochetal forms
and round body forms but not more resistant aggregated biofilm-like microcolony
persisters enriched in stationary phase cultures. Moreover, we found that not all drugs
are suitable for pulse dosing, with bactericidal drugs ceftriaxone and cefuroxime being
more appropriate for pulse dosing than bacteriostatic drug doxycycline and persister
drug daptomycin. We also showed that drug combination pulse dosing treatment was
more effective than single drug pulse dosing. Importantly, we demonstrate that pulse
dosing treatment impaired the activity of the persister drug daptomycin and its drug
combination against B. burgdorferi persisters and that the most effective way to kill
the more resistant biofilm-like microcolonies is the daptomycin/doxycycline/ceftriaxone
triple drug combination without pulse dosing. Our findings indicate pulse dosing may
not always work as a general principle but rather depends on the specific drugs used,
with cidal drugs being more appropriate for pulse dosing than static or persister drugs,
and that drug combination approach with persister drugs is more effective at killing the
more resistant microcolony form of persisters than pulse dosing. These observations
may have implications for more effective treatment of Lyme disease. Future studies are
required to validate these findings in animal models of B. burgdorferi persistence.
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INTRODUCTION
Lyme disease, caused by Borrelia burgdorferi, is the most
common vector-borne disease in the United States with an
estimated 300,000 cases in 2013 (CDC, 2015a). The infection is
transmitted to humans by tick vectors that feed upon rodents,
reptiles, birds, and deer (Radolf et al., 2012). In the early stage
of Lyme disease, patients often have localized erythema migrans
skin lesions, but late stage Lyme disease is a disseminated multi-
system disorder with signs and symptoms including arthritis,
carditis, and neurologic impairment (CDC, 2015a). The majority
of Lyme disease patients can resolve their symptoms if treated
promptly with doxycycline, amoxicillin, or cefuroxime (Wormser
et al., 2006). However, at least 10–20% of Lyme disease patients
have lingering symptoms such as fatigue, muscular and joint
pain, and neurologic impairment, 6 months after the standard
2–4 week antibiotic treatment, a collection of symptoms called
Post-Treatment Lyme Disease Syndrome (PTLDS; CDC, 2015b).
While the cause of PTLDS is unknown, there are several
theories, including co-infections (Swanson et al., 2006),
autoimmune response (Steere et al., 2001), immune response
to continued presence of antigenic debris (Bockenstedt et al.,
2012), as well as B. burgdorferi persisters that are not killed by the
current antibiotics (Hodzic et al., 2008, 2014; Embers et al., 2012).
Using xenodiagnosis and quantitative PCR, various studies have
found evidence of B. burgdorferi persistence in dogs (Straubinger
et al., 1997), mice (Hodzic et al., 2008, 2014), monkeys (Embers
et al., 2012), and humans (Marques et al., 2014) after antibiotic
treatment, though no viable bacteria could be cultured.
Recently, B. burgdorferi has been shown to develop persisters
in stationary phase cultures in vitro, which are tolerant to
the antibiotics used to treat Lyme disease (Feng et al., 2014a,
2015a; Caskey and Embers, 2015; Sharma et al., 2015). These
persister bacteria have an altered gene expression profile, which
may underlie their phenotypic drug tolerance (Feng et al.,
2015c). In log phase cultures (3–5 day old), B. burgdorferi is
primarily in motile spirochetal form and is highly susceptible
to current Lyme antibiotics doxycycline and amoxicillin (Feng
et al., 2014a, 2015a). However, in stationary phase cultures
(7–15 day old), increased numbers of atypical morphological
variants such as round bodies and aggregated biofilm-like
microcolonies develop (Feng et al., 2014a, 2015a). These atypical
forms can be considered part of the heterogeneous persisters
(Zhang, 2014) as they have high tolerance to doxycycline and
amoxicillin compared to growing spirochetal forms (Feng et al.,
2014a, 2015a). Therefore, stationary phase cultures (7–15 day
old) which are enriched in persisters have been used as a
surrogate persister model for high-throughput drug screens
against persister populations (Feng et al., 2014a, 2015a,b,d) and
have been shown to have overlapping persister populations with
amoxicillin tolerant round body persisters (Feng et al., 2016a).
Drugs with high activity against the B. burgdorferi stationary
phase persisters were identified through screens of FDA approved
drug library and NCI compound library (Feng et al., 2014a,
2015a,b,d). Among them, daptomycin, a lipopeptide antibiotic
targeting bacterial cell membranes used to treat MRSA, has the
highest activity against B. burgdorferi persisters (Feng et al.,
2014a). Although the anti-persister drugs such as daptomycin
are more active than the current Lyme antibiotics such as
doxycycline or amoxicillin against B. burgdorferi persisters (Feng
et al., 2014a), they alone could not completely eradicate the more
resistant biofilm-like microcolonies and a drug combination
approach is required to do so (Feng et al., 2015a). The more
effective drug combination approach to eradicate biofilm-like
microcolonies is consistent with the drug combination principle
for treatment of persistent infections like tuberculosis (Zhang
et al., 2012; Zhang, 2014). In a recent study, ceftriaxone
pulse dosing was shown to completely eradicate B. burgdorferi
persisters using a relatively young 5 day old late log phase culture
(Sharma et al., 2015), which is known to primarily consist of
spirochetal form that is more susceptible to antibiotics. It is
unclear whether the pulse dosing approach is able to eradicate
the more resistant microcolony form of persisters (Feng et al.,
2015a). In this study, we evaluated the pulse dosing approach
with ceftriaxone and also other Lyme antibiotics and drug
combinations using an older stationary phase culture (10 day
old) enriched with more resistant biofilm-like microcolonies
as well as a 5 day old late log phase culture as a control to
determine their ability to eradicate B. burgdorferi persisters.
We found that four rounds of pulse dosing treatment with
ceftriaxone could eliminate mainly the planktonic spirochetal
form of B. burgdorferi in the log phase and the stationary phase
culture, but failed to eradicate the aggregated microcolony form
of B. burgdorferi persisters in the stationary phase culture.
MATERIALS AND METHODS
Strain, Media, and Culture
Low passaged B. burgdorferi strain B31 5A19 was kindly
provided by Monica Embers (Caskey and Embers, 2015). The
B. burgdorferi B31 strain was cultured in BSK-H medium
(HiMedia Laboratories Pvt. Ltd.), with 6% rabbit serum (Sigma–
Aldrich) in microaerophilic incubator (33◦C, 5% CO2) without
antibiotics. After incubation for 7–10 days, 1 ml stationary phase
B. burgdorferi culture was transferred into 1.5 ml Eppendorf tubes
for evaluating the effect of antibiotic treatment.
Antibiotics
Doxycycline (Dox), cefuroxime, ceftriaxone (CefT; Sigma–
Aldrich, USA), and daptomycin (Dap) (AK Scientific Inc.,
USA) were dissolved in suitable solvents as suggested by the
Clinical and Laboratory Standards Institute (CLSI) to obtain
stock solutions. The antibiotic stocks were filter-sterilized by
0.2 µm filter. Then the stocks were stored at−20◦C.
Microscopy Techniques
The B. burgdorferi cultures were examined using a Zeiss
AxioImager M2 microscope with epifluorescence illumination.
Pictures were taken using a SPOT slider camera. The SYBR Green
I/PI viability assay was performed to assess cell viability using
the ratio of green/red fluorescence to determine the live:dead cell
ratio, respectively, as described previously (Feng et al., 2014b,
2015a). This residual cell viability reading was confirmed by
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analyzing three representative images of the bacterial culture
using epifluorescence microscopy. Image Pro-Plus software was
used to quantitatively determine the fluorescence intensity
(Shopov et al., 2000).
Pulse Dosing Treatment
Aliquots of a 10 day old stationary phase culture (1 ml) of
B. burgdorferi and a 5 day old late log phase culture (as a control)
were treated with single antibiotic or drug combinations (all at
5 µg/ml) for 5 days in Eppendorf tubes, which is considered the
first round of antibiotic treatment. Then the cultures were washed
twice and resuspended in fresh BSK-H medium for recovery for
1 day at 33◦C without shaking. Then the culture was treated
again with drugs or drug combinations for another 5 days to give
the second round of treatment. This was repeated for a total of
four rounds of treatment. To determine the effect of antibiotics,
100 µl of treated B. burgdorferi culture was transferred to a 96-
well plate and the SYBR Green I/PI viability assay was used
to assess the live and dead cells after antibiotic exposure as
described (Feng et al., 2014a). Briefly, 10 µl of SYBR Green I/PI
staining mixture was added to each well and mixed thoroughly.
The plates were incubated at room temperature in the dark for
15 min followed by plate reading at excitation wavelength at
485 nm and fluorescence intensity at 535 nm (green emission),
and 635 nm (red emission) in microplate reader (HTS 7000 plus
Bio Assay Reader, PerkinElmer Inc., USA). With least-square
fitting analysis, the regression equation and regression curve of
the relationship between percentage of live bacteria and green/red
fluorescence ratios were obtained. The regression equation was
used to calculate the percentage of live cells in each well of the
96-well plate. At the same time, microscopy followed by SYBR
Green I/PI staining was used to confirm the results of plate reader
as previously described (Feng et al., 2014a).
Subculture Studies to Assess Viability of
Antibiotic-Treated B. Burgdorferi
After four rounds of pulse dosing treatment, the bacteria were
spun down and washed twice with 1 mL fresh BSK-H medium.
The cell pellet was resuspended in 600 µl BSK-H medium, and
a 200 µl aliquot was used to inoculate a new tube of 1 ml fresh
BSK-H medium for subculture. The cultures were allowed to
grow for up to 21 days, when they were evaluated for regrowth
with viable cells using the SYBR Green I/PI assay and
epifluorescence microscopy as previously described (Feng et al.,
2015a).
RESULTS
Ceftriaxone Pulse Dosing Sterilized Log
Phase Culture But Fails to Do so for
Stationary Phase B. burgdorferi Culture
Enriched with More Resistant
Biofilm-Like Microcolonies
Ceftriaxone is one of the best clinically used antibiotics for
treating late stage Lyme disease (Dattwyler et al., 1988) and
has been shown to have good activity against B. burgdorferi
persisters (Feng et al., 2014a). A previous study showed that
four rounds of ceftriaxone pulse dosing treatment could eradicate
late log phase culture (5 day old) below the limit of detection
(Sharma et al., 2015). To determine if the pulse dosing treatment
is able to eradicate older stationary phase culture containing
more resistant microcolony form of persisters, we compared
pulse dosing treatment with ceftriaxone (5 µg/ml) on a 10 day
old stationary phase culture of B. burgdorferi and on a 5 day
old late log phase culture as a control using procedures as
described previously (Sharma et al., 2015). As shown in our
previous studies (Feng et al., 2014a, 2015a), the spirochetal
form dominated the 5 day old log phase culture, with few
round body forms and rare microcolony forms, whereas truly
stationary phase cultures developed increasing proportions of
variant forms such as round bodies and microcolonies that
are more resistant to antibiotics. As the round of pulse
dosing treatment with ceftriaxone increased, the number of
spirochetal forms and round body forms decreased in the
log phase culture (Figures 1A–D). We noted after the first
round of ceftriaxone treatment the number of planktonic
spirochetes decreased dramatically while the number of round
body forms increased slightly presumably due to conversion
of spirochetal form to round body forms (Feng et al., 2016a)
in both the 5 day old late log phase and the 10 day old
stationary phase cultures. Two and three rounds of treatment
could kill both spirochetal form and round body forms,
and the fourth round of treatment eliminated nearly all
planktonic B. burgdorferi cells but still could not eliminate
the aggregated microcolony form in the 10 day stationary
phase culture (Figure 1H). The large portions of microcolony
forms (Feng et al., 2015a) not killed by pulse dosing treatment
(Figures 1E–H), could be seen by SYBR Green I/PI assay
with green fluorescence despite four rounds of ceftriaxone
pulse dosing (Figure 1H). In the meantime, we used drug
free control in the four rounds of pulse dosing treatment
to eliminate the possible influence of frequent centrifugation
and washes on loss of bacteria and found that these steps
did not significantly affect the results of the pulse dosing
experiment.
To confirm the results of the SYBR Green I/PI microscopy
assay, we performed subculture test in fresh BSK-H medium as
in our previous study (Feng et al., 2015a). The results showed
that the 5 day log phase culture treated with four rounds of
ceftriaxone pulse dosing did not regrow after 7 and 21 days
subculture (Figures 1I,J). The four rounds of ceftriaxone pulse
dosing treated 10 day old stationary phase culture did not show
signs of regrowth after 7 day subculture despite the presence of
some microcolony forms of B. burgdorferi (Figure 1K). However,
after 21 day subculture, about 3 × 106 regenerative spirochetes
per milliliter in the stationary phase subculture were observed
(Figure 1L). These results suggest that although four rounds of
ceftriaxone pulse dosing treatment could eliminate planktonic
log phase B. burgdorferi spirochetal forms and even round
body forms, it failed to eradicate the more resistant aggregated
microcolony forms of B. burgdorferi in the stationary phase
culture.
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FIGURE 1 | Effect of ceftriaxone pulse dosing on 5 day old log phase and 10 day old stationary phase Borrelia burgdorferi cultures. Log phase (A–D, I,
and J) and stationary phase (E–H, K, and L) B. burgdorferi cultures were treated with pulse dosing of 5 µg/mL ceftriaxone as described in the section “Materials
and Methods” followed by staining by SYBR Green I/PI assay and fluorescence microscopy at 100× magnification. Abbreviation: Sta., stationary.
Drugs Differ Considerably in Their Ability
to Sterilize B. Burgdorferi Cultures in
Pulse Dosing Treatment
Since ceftriaxone pulse dosing could eradicate B. burgdorferi
in log phase cultures but not in stationary phase cultures, we
wanted to investigate how persister active drug daptomycin
and other Lyme antibiotics such as doxycycline and cefuroxime
behave in the pulse dosing experiment. We subjected a
10 day old stationary phase culture of B. burgdorferi to
daptomycin, doxycycline, and cefuroxime all at 5 µg/ml
with ceftriaxone as a positive control to four rounds of
pulse dosing treatment as described in the section “Materials
and Methods.” Our results showed that daptomycin was
less effective (residual viability 67%) than ceftriaxone
(residual viability 42%) and had comparable activity with
doxycycline (residual viability 64%) after four rounds of pulse
dosing treatment (Figure 2A). Interestingly, cefuroxime
had comparable activity (41% residual viable cells) as
ceftriaxone (42% residual viable cells) after four rounds of
pulse dosing treatment (Figure 2A). In subculture studies,
all the cultures subjected to four rounds of single drug
pulse dosing treatment with daptomycin, or doxycycline,
or cefuroxime, or ceftriaxone grew back after 21 days
(Figure 2B), indicating single antibiotic pulse dosing
is not able to eradicate stationary phase B. burgdorferi
cultures.
Drug Combination Is More Effective than
Single Drug in Pulse Dosing Treatment
Despite the good activity of ceftriaxone pulse dosing treatment
against log phase culture of B. burgdorferi (Figures 1A–D) it
had poor activity against the most resistant microcolony form
of persisters in stationary phase cultures (Figures 1E–H). Our
previous studies suggest that drug combination treatment is
more effective than single drug treatment and could eradicate
the B. burgdorferi microcolony forms in vitro (Feng et al.,
2015a, 2016a,b) and that daptomycin showed best activity against
stationary phase and round body form of B. burgdorferi (Feng
et al., 2014a, 2016a). The daptomycin/doxycycline combined
with cefoperazone or cefuroxime is the most effective drug
combination which could eradicate even the most resistant
aggregated microcolony form of B. burgdorferi enriched in
stationary phase cultures (Feng et al., 2015a, 2016b). To
determine if daptomycin drug combinations could eradicate the
stationary phase B. burgdorferi in the pulse dosing treatment,
we tested drug combination pulse dosing treatment on a
10 day old B. burgdorferi stationary phase culture enriched
with microcolony forms at 5 µg/ml of each drug (close to
the plasma concentration). We found that the daptomycin
combination pulse dosing treatment (residual viability 25–34%)
were obviously better than the single drug pulse dosing treatment
(Figures 3A and 2A). On the other hand, the ceftriaxone and
doxycycline combination did not produce significantly better
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FIGURE 2 | Representative images of a 10 day old B. burgdorferi stationary phase culture treated with four rounds of pulse dosing treatment with
different single drugs (Aa–d) and subcultured for 21 days in fresh BSK-H medium (Ba–d). Stationary phase B. burgdorferi culture (10 day old) was treated with
different single drug (5 µg/ml) pulse dosing treatment as described in the section “Materials and Methods,” followed by staining by SYBR Green I/PI assay and
fluorescence microscopy at 100× magnification. The percentage of residual viable cells is shown in brackets. The percentage of residual viable cells was calculated
according to the regression equation and green/red fluorescence ratios. None of the single drugs were able to eradicate the microcolony forms as shown by either
SYBR Green I/PI staining or subculture studies. Abbreviations: CefT, ceftriaxone; CefU, cefuroxime; Dox, doxycycline; Dap, daptomycin.
activity (residual viability 40%; Figure 3Ac) than the ceftriaxone
alone (residual viability 42%; Figure 2Aa) after four rounds of
pulse dosing treatment.
In three drug combination (ceftriaxone/doxycycline/dapto-
mycin) pulse dosing, the treatment showed better activity
(residual viability 25%) than two drug combination pulse
dosing treatments (residual viability 40–28%; Figure 3A).
Among the two drug combination pulse dosing treatments,
doxycycline/daptomycin combination showed the best
activity (residual viability 28%), and ceftriaxone/daptomycin
combination showed better activity (residual viability
34%), while the ceftriaxone/doxycycline showed least
activity (residual viability 40%). However, we found that
the above drug combination pulse dosing treatments all
failed to eradicate the microcolony forms (Figure 3A).
Interestingly, we found the triple drug combination treatment
(ceftriaxone/doxycycline/daptomycin) without pulse dosing
was the most effective among all drug combinations tested
and was more active (residual viability 19%) than the same
triple drug combination with pulse dosing treatment (residual
viability 42%). The three drug combination treatment without
pulse dosing eradicated virtually all visible B. burgdorferi cells
including the aggregated microcolony form (Figure 3A), while
after four rounds of the three drug combination pulse dosing
treatment some aggregated microcolony forms were still observe
persisting (Figure 3A).
To confirm the results of the SYBR Green I/PI assay, we
performed subculture experiment on the drug combination
pulse dosing treated 10 day old B. burgdorferi stationary
phase cultures. The results showed that cultures treated
with two drug combination pulse dosing (CefT+Dap;
Dox+Dap, CefT+Dox) all grew up after 21 day subculture
(Figures 3Ba–c). Interestingly, the triple drug combination
(ceftriaxone/doxycycline/daptomycin) pulse dosing failed
to eradicate B. burgdorferi in the subculture test as shown
by regrowth of visible spirochetal organisms after 21 days
(Figure 3Bd), by contrast, the same triple drug combination
(ceftriaxone/doxycycline/daptomycin) without pulse dosing
completely eradicated all B. burgdorferi including the most
resistant microcolonies as demonstrated by lack of any regrowth
in subculture (Figure 3Be).
DISCUSSION
A previous study showed that ceftriaxone could eliminate all
cells including persisters in a 5 day old B. burgdorferi culture
after four rounds of pulse dosing treatment (Sharma et al., 2015).
In this study, we were able to confirm this finding using the
same protocol with a relatively young 5 day old late log phase
B. burgdorferi culture. However, we found that although four
rounds of ceftriaxone pulse dosing treatment could eliminate
nearly all planktonic spirochetes in the 5 day old culture and
even those in a 10 day old stationary phase B. burgdorferi
culture, it failed to eradicate the more resistant aggregated
biofilm-like microcolonies enriched in stationary phase cultures
(Figure 1). Our previous studies demonstrated that a 5 day old
culture is quite young and could be considered late log phase
(Feng et al., 2014a) rather than “stationary phase” as used in a
previous study (Sharma et al., 2015) and is mainly consisting of
spirochetal organisms that are more susceptible to antibiotics.
In contrast, 7–10 day old cultures of B. burgdorferi can be
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FIGURE 3 | Representative images of a 10 day old B. burgdorferi stationary phase culture treated with drug combination pulse dosing treatment
(Aa–f) and subcultured for 21 days in fresh BSK-H medium (Ba–f). Stationary phase B. burgdorferi culture (10 day old) was treated with pulse dosing treatment of
two drug combinations (CefT+Dap; Dox+Dap, CefT+Dox) or the three drug combination (ceftriaxone/doxycycline/daptomycin; 5 µg/ml) followed by staining with
SYBR Green I/PI assay and fluorescence microscopy at 100× magnification. The percentage of residual viable cells is shown in brackets. The percentage of residual
viable cells was calculated according to the regression equation and green/red fluorescence ratios as described in the section “Materials and Methods.”
Abbreviations: CefT, ceftriaxone; Dox, doxycycline; Dap, daptomycin.
considered true stationary phase and contain higher proportions
of aggregated microcolony forms, which are much more tolerant
to antibiotics than the spirochetal forms (Feng et al., 2015a).
Thus, it is not surprising that ceftriaxone failed to eradicate the
more resistant biofilm-like microcolonies of B. burgdorferi as
shown in this study (Figure 1), as heterogeneous microcolonies
have previously been shown to be highly tolerant to antibiotics
including single drugs as well as many drug combinations except
daptomycin/doxycycline/cefoperazone (Feng et al., 2015a). In
addition, a short 1 day recovery in fresh medium used in this
study per the previous pulse dosing protocol (Sharma et al., 2015)
may not be sufficiently long to allow all the dormant forms in
aggregated microcolonies to wake up and become susceptible to
ceftriaxone. Indeed, the time interval in between pulse dosing
treatment needed to allow the persisters to revive and become
susceptible to antibiotics is hard to determine not only for in vitro
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persisters but also for in vivo persisters in patients, considering
the heterogeneity of the bacteria and the disease and individual
differences in immune control, which could pose significant
challenges to the use of pulse dosing in clinical settings (Zhang,
2014).
An important observation of this study is that pulse dosing
may not always work as a principle against persisters but rather its
effect depends on the particular drugs being used and that not all
drugs are suitable for pulse dosing. We found that daptomycin,
which is the most effective antibiotic against B. burgdorferi
persisters (Feng et al., 2014a, 2016a), fared poorly in pulse dosing
experiments either singly (Figure 2A) or in drug combinations
(Figure 3A), as it had even less activity than the ceftriaxone and
doxycycline in the pulse dosing treatment (Figure 2A). Despite
its excellent activity against non-growing B. burgdorferi persisters
(Feng et al., 2014a), daptomycin is known to have limited activity
against growing spirochetal forms as shown by a relatively high
MIC (12.5–25 µg/ml) compared to ceftriaxone and doxycycline
(Feng et al., 2014a). When used at a concentration under its
MIC (5 µg/ml) as in this study, daptomycin is expected to
have little activity against growing B. burgdorferi thus explaining
its poor activity in the pulse dosing treatment. However, we
do find better activity when daptomycin was combined with
antibiotics such as ceftriaxone and doxycycline which act on
actively growing bacteria even in the pulse dosing experiment
(Figure 2A). The basic idea of pulse dosing treatment is to
allow non-growing antibiotic tolerant persisters formed after
drug treatment to recover and become growing spirochetes so
they become susceptible to drugs again. Thus, pulse dosing seems
to work well with cidal antibiotics as shown with ceftriaxone
(Sharma et al., 2015) (Figure 1) and cefuroxime (Figure 2A)
but not with static drugs like doxycycline (Caskey and Embers,
2015) (Figure 2Ac) and persister drugs such as daptomycin as
shown in this study (Figure 2A). Our findings suggest that only
bactericidal antibiotics like cephalosporins may be suitable for
pulse dosing but not bacteriostatic agents or persister drugs.
These observations may have important implications on clinical
use of pulse dosing for treatment of persistent infections like
Lyme disease.
Given the role of pulse dosing with cidal antibiotics, its
effect as a single drug on the more resistant microcolonies
is limited and could not eradicate aggregated biofilm-like
structures (Figure 1). In our previous studies, we found that
drug combinations containing persister drug daptomycin are
more effective against B. burgdorferi persisters than single drug
treatment (Feng et al., 2015a, 2016b). Consistent with this, we
found that the drug combination pulse dosing treatment also
showed more activity against stationary phase B. burgdorferi
than single drug pulse dosing (Figures 3A and 2A). This is
supported by microscopic observations that the amount and the
size of the aggregated microcolonies were significantly reduced
after the drug combination pulse dosing treatment compared
with the single drug pulse dosing treatments (Figure 3A). In
addition, three drug combination pulse dosing treatment was
more effective than two drug combination pulse dosing treatment
(Figure 3A). However, either the two drug combination or
even three drug combination pulse dosing were still unable to
eradicate the more resistant microcolony forms, and the residual
microcolonies grew up again in the subculture test without
antibiotics (Figure 3B).
We previously showed that daptomycin/doxycycline comb-
ined with cefoperazone or cefuroxime as a triple drug
combination has the best activity against stationary phase
B. burgdorferi cultures and could completely eradicate all bacteria
including the most resistant aggregated microcolony form of
persisters (Feng et al., 2015a, 2016b). In this study, we found
the ceftriaxone or cefuroxime could also replace cefoperazone in
the daptomycin/doxycycline combination to kill all the stationary
phase B. burgdorferi cells (Figure 3). Unexpectedly, however,
the triple drug combination daptomycin/doxycycline/ceftriaxone
pulse dosing treatment turned out to be less effective than the
continuous triple drug combination treatment as shown by SYBR
Green I/PI assay as well as the subculture test (Figure 3). Thus
pulse dosing treatment compromised the activity of daptomycin-
containing drug combinations through reducing the activity of
daptomycin as shown in Figure 2Ad. Further studies are required
to validate the findings of these in vitro studies in vivo and
compare the utility of the pulse dosing and the drug combination
treatment in eradication of borrelia persistence phenomenon in
animal models.
CONCLUSION
We found that four rounds of ceftriaxone pulse dosing could
eradicate planktonic log phase B. burgdorferi spirochetal forms
and round body forms but not the more resistant aggregated
biofilm-like microcolony forms in the stationary phase culture.
In addition, we showed that not all drugs are appropriate
for pulse dosing, with ceftriaxone and cefuroxime being more
suitable for pulse dosing than bacteriostatic drug doxycycline and
persister drug daptomycin. This study also demonstrated that
drug combination pulse dosing treatment is more effective than
single drug pulse dosing. Importantly, we found that pulse dosing
could impair the activity of the persister drug daptomycin and its
drug combination on B. burgdorferi persisters and that the more
effective way to kill the aggregated biofilm-like microcolony form
of persisters is the triple daptomycin drug combination without
pulse dosing. Future studies are needed to validate these findings
in animal studies and clinical trials.
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